Status:
COMPLETED
Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia
Lead Sponsor:
Cengiz Gokcek Women's and Children's Hospital
Conditions:
Preeclampsia
Eligibility:
FEMALE
18-40 years
Brief Summary
Introduction: The etiology/pathophysiology of preeclampsia remains an enigma. Cellular immunity is a key factor in the etiology of late-onset preeclampsia (L-PrE). Presepsin is split out from the phag...
Detailed Description
This observational case-control study was designed at Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey, in the Department of Obstetrics and Gynecology between June 2018 and January 201...
Eligibility Criteria
Inclusion
- preeclampsia healthy pregnancy
Exclusion
- pregnant women with any systemic condition (such as chronic hypertension, inflammatory and rheumatic diseases),
- using any kind of medication throughout pregnancy (such as acetylsalicylic acid, corticosteroids or heparin),
- pregnant women who had fever at the time of the first admission,
- concurrent infections (urinary tract infection, cervicitis, etc.),
- pregnancies complicated with premature membrane rupture or chorioamnionitis,
- history of medication for PE treatment at the time of the first admission,
- patients who had fetal congenital abnormalities or genetic syndromes,
- drug user,
- multiple gestations,
- active labor.
Key Trial Info
Start Date :
June 6 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04126902
Start Date
June 6 2018
End Date
September 30 2019
Last Update
October 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cengiz Gokcek Women's and Child's hospital
Gaziantep, Turkey (Türkiye), 27010